ADB-BINACA

ADB-BINACA (also known as ADMB-BZINACA using EMCDDA naming standards^[1]) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products.^[2] It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB₁ receptor with a binding affinity (K_i) of 0.33 nM and an EC₅₀ of 14.7 nM.^[3]

ADB-BINACA

Legal status
Legal status	CA: Schedule II DE: NpSG (Industrial and scientific use only) UK: Class B US: Schedule I
Identifiers
IUPAC name N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-benzyl-1H-indazole-3-carboxamide
CAS Number	1185282-27-2 Y
PubChem CID	129406620
ChemSpider	57621565
UNII	PUVP61SOSI
CompTox Dashboard (EPA)	DTXSID501344812
Chemical and physical data
Formula	C21H24N4O2
Molar mass	364.449 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(NC(C(N)=O)C(C)(C)C)C1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3
InChI InChI=1S/C21H24N4O2/c1-21(2,3)18(19(22)26)23-20(27)17-15-11-7-8-12-16(15)25(24-17)13-14-9-5-4-6-10-14/h4-12,18H,13H2,1-3H3,(H2,22,26)(H,23,27) Key:IUFIUAWRCUVUCQ-UHFFFAOYSA-N

Adb-Butinaca

The analogue with a 1-butyl substitution on the indazole ring rather than 1-benzyl has also been sold as a designer drug under the name ADB-BINACA, but is now more commonly referred to as ADB-BUTINACA to avoid confusion with the benzyl compound.^{[4][5][6][7][8]} It is a similarly potent CB₁ agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an EC₅₀ of 6.36 nM for CB1.^[9][10]

See also

• 4F-MDMB-BINACA
• 5F-AB-PINACA
• 5F-ADB
• 5F-ADB-PINACA
• ADB-CHMINACA
• ADB-FUBICA
• ADB-FUBINACA
• ADB-HEXINACA
• ADB-PINACA
• ADB-4en-PINACA